OPERATIONAL clinical trial stops

Unknown Borderline Personality Disorder trial by Icahn School of Medicine at Mount Sinai. Stop reason: OPERATIONAL.

Study was halted during COVID pandemic. However, PI is currently reconnecting with a compounding pharmacy to re-establish supply of the oxytocin and updating cost estimates. We are hoping to resume the pilot work with oxytocin once it is clarified.

Phase II Medium-chain Acyl-CoA Dehydrogenase Deficiency trial by Jerry Vockley, MD, PhD. Stop reason: OPERATIONAL.

funding was pulled

Phase IV Post-traumatic Stress Disorder trial by University of California, San Francisco. Stop reason: OPERATIONAL.

Unable to meet enrollment goals

Phase III Secondary Hyperparathyroidism-Chronic Kidney Disease trial by Sanofi. Stop reason: OPERATIONAL.

The study was conducted to fulfill a post-marketing commitment (PMC).FDA acknowledged the fulfillment of this PMC.

Phase IV Sedation trial by Nanfang Hospital, Southern Medical University. Stop reason: OPERATIONAL.

The trial was terminated early because additional sites did not recruit as planned, making the multicenter sample size infeasible. Enrollment ended after 117 participants were randomized at Nanfang Hospital, unrelated to safety, efficacy, or outcomes

Phase I Borderline Resectable Pancreatic Adenocarcinoma trial by University of Utah. Stop reason: OPERATIONAL.

Closed due to slow accrual

Phase II Advanced Biliary Tract Cancer(BTC) trial by National Health Research Institutes, Taiwan. Stop reason: OPERATIONAL.

The study was terminated due to administrative reasons following the cancellation of collaboration between the involved parties.

Phase I Non-Small Cell Lung Cancer trial by National Cancer Institute (NCI). Stop reason: OPERATIONAL.

Revisions to eligibility/design being made prior to enrollment of first participants.

Phase I Advanced Solid Tumor trial by Selecxine. Stop reason: OPERATIONAL.

Business decision

Phase I Multiple Myeloma trial by National Cancer Institute (NCI). Stop reason: OPERATIONAL.

Administrative hold pending non-safety related changes to the study design.

Phase II Medium-chain Acyl-CoA Dehydrogenase Deficiency trial by Jerry Vockley, MD, PhD. Stop reason: OPERATIONAL.

Funding was pulled

Phase I Metastatic Pancreatic Ductal Adenocarcinoma trial by Fred Hutchinson Cancer Center. Stop reason: OPERATIONAL.

Study terminated due to end of funding.

Phase I Recurrent Plasma Cell Myeloma trial by City of Hope Medical Center. Stop reason: OPERATIONAL.

Slow/Low Accrual

Phase I Acute Lymphoblastic Leukemia trial by City of Hope Medical Center. Stop reason: OPERATIONAL.

Accrual goal

Phase I Pancreatic Cancer trial by M.D. Anderson Cancer Center. Stop reason: OPERATIONAL.

PI Request

Phase I Cutaneous Melanoma trial by Seagen, a wholly owned subsidiary of Pfizer. Stop reason: OPERATIONAL.

The trial was terminated for strategic reasons. The decision was not based on any safety concerns.

Phase II Mucinous Adenocarcinoma of the Rectum trial by University of Southern California. Stop reason: OPERATIONAL.

Insufficient Accrual

Phase I HER2-positive Breast Cancer trial by University of Alabama at Birmingham. Stop reason: OPERATIONAL.

Unable to recruit for this study.

Phase I Prostate Cancer trial by Washington University School of Medicine. Stop reason: OPERATIONAL.

Low accrual

Phase III Solitary Osseous Plasmacytoma trial by Alliance for Clinical Trials in Oncology. Stop reason: OPERATIONAL.

DSMB recommendation due to slow accrual

Early Phase I Opioid Use Disorder trial by Jacques E. Chelly. Stop reason: OPERATIONAL.

Study did not receive funding.

Phase II PPROM trial by The University of Texas Medical Branch, Galveston. Stop reason: OPERATIONAL.

Low study recruitment

Phase II RSV Infection trial by Gilead Sciences. Stop reason: OPERATIONAL.

Study was terminated by Sponsor; the decision was not due to any safety findings.

Phase III Asthma trial by Hoffmann-La Roche. Stop reason: OPERATIONAL.

Sponsor decision to discontinue lebrikizumab development for the treatment of asthma.

Phase I High Risk Neuroblastoma trial by National Cancer Institute (NCI). Stop reason: OPERATIONAL.

Drug supply issues

Phase I Leukodystrophy, Globoid Cell trial by Gemma Biotherapeutics. Stop reason: OPERATIONAL.

The study was stopped due to changes in the company strategy.

Phase II Post Traumatic Stress Disorder trial by Global Coalition for Adaptive Research. Stop reason: OPERATIONAL.

The trial has been temporarily suspended due to administrative issues

Phase IV Appendicitis trial by University of California, San Francisco. Stop reason: OPERATIONAL.

Not feasible to complete trial due to low enrollment rate. Enrollment terminated and inadequately powered to achieve statistical significance on primary and secondary study outcomes.

Phase II Post Traumatic Stress Disorder trial by Global Coalition for Adaptive Research. Stop reason: OPERATIONAL.

The trial has been temporarily suspended due to administrative issues

Phase III Surgical Site Infection trial by PolyPid Ltd.. Stop reason: OPERATIONAL.

company prioritization reasons

Phase III Osteoporosis trial by University of Texas Southwestern Medical Center. Stop reason: OPERATIONAL.

No enrollment due to COVID

Phase II Uterine Leiomyosarcoma trial by M.D. Anderson Cancer Center. Stop reason: OPERATIONAL.

PI Request

Early Phase I Epidural Spinal Tumors trial by Wake Forest University Health Sciences. Stop reason: OPERATIONAL.

Low accruals

Phase II Covid19 trial by HonorHealth Research Institute. Stop reason: OPERATIONAL.

Closed due to poor enrollment

Phase IV Familial Mediterranean Fever (FMF ) trial by Swedish Orphan Biovitrum. Stop reason: OPERATIONAL.

Business decision.

Phase III Degenerative Disc Disease trial by Angitia Biopharmaceuticals. Stop reason: OPERATIONAL.

Sponsor's strategic decision not related to safety concerns.

Phase IV Drug-resistant Focal Seizure trial by Beth Israel Deaconess Medical Center. Stop reason: OPERATIONAL.

Failure to recruit subjects.

Phase I Healthy trial by Pfizer. Stop reason: OPERATIONAL.

The study was terminated for business reasons; there were no safety concerns.

Phase II Myelofibrosis trial by Incyte Corporation. Stop reason: OPERATIONAL.

The decision to close the study was made due to the expiration of remaining drug supply.

Phase IV Congenital Hypothyroidism trial by IBSA Institut Biochimique SA. Stop reason: OPERATIONAL.

Inability to recruit subjects

Phase I Prostatic Neoplasms trial by National Cancer Institute (NCI). Stop reason: OPERATIONAL.

Slow/insufficient accrual

Phase I Coronavirus trial by Celularity Incorporated. Stop reason: OPERATIONAL.

Lack of enrollment due to COVID treatment options availability.

Phase III Migraine trial by Eli Lilly and Company. Stop reason: OPERATIONAL.

Study terminated due to strategic business decision

Unknown Heart Failure (for Example, Fluid Overload) trial by Nuwellis, Inc.. Stop reason: OPERATIONAL.

The study was stopped early due to slow enrollment and was a business decision. This decision was not based on any efficacy or safety concerns.

Phase I Relapsing Multiple Sclerosis (RMS) trial by Cabaletta Bio. Stop reason: OPERATIONAL.

The study was withdrawn prior to site activation and before enrollment of any participants due to sponsor decision to reprioritize the development portfolio.

Phase III Metastatic Breast Cancer trial by SOLTI Breast Cancer Research Group. Stop reason: OPERATIONAL.

The study was prematurely halted because enrollment was significantly delayed compared with the original projections due to the evolving therapeutic landscape.

Phase I Infertility trial by ART Fertility Clinics LLC. Stop reason: OPERATIONAL.

Difficulty of enrolling and recruiting patients

Phase II Osteochondrodysplasia trial by Sanofi. Stop reason: OPERATIONAL.

Sponsor decision. Not related to safety concern.

Phase III Early Alzheimer's Disease trial by Alzheon Inc.. Stop reason: OPERATIONAL.

Sponsor business decision

Phase I Metastatic Castration-Resistant Prostate Carcinoma trial by National Cancer Institute (NCI). Stop reason: OPERATIONAL.

Other - To assess the study's feasibility.

Phase II Myocardial Infarction trial by Boehringer Ingelheim. Stop reason: OPERATIONAL.

Sponsor decision

Phase II Groin Injury trial by University Hospital, Bordeaux. Stop reason: OPERATIONAL.

target number of patient not reached and lost of financial supplies

Phase II Colorectal Cancer trial by University of Southampton. Stop reason: OPERATIONAL.

funding withdrawal

Phase II Hepatocellular Carcinoma trial by Assistance Publique - Hôpitaux de Paris. Stop reason: OPERATIONAL.

Because patient recruitment was affected by the COVID-19 pandemic, the study sponsor and funding partner halted enrollment at that time to meet contractual obligations

Phase II Myocardial Infarction trial by Alexion Pharmaceuticals, Inc.. Stop reason: OPERATIONAL.

Administrative reasons.

Early Phase I End Stage Renal Disease trial by Mayo Clinic. Stop reason: OPERATIONAL.

Unable to enroll patients for the trial.

Phase I Carcinoma, Non-Small-Cell Lung trial by Seagen, a wholly owned subsidiary of Pfizer. Stop reason: OPERATIONAL.

The trial was terminated for strategic reasons. The decision was not based on any safety concerns

Phase IV Transformed Migraine trial by Rutgers, The State University of New Jersey. Stop reason: OPERATIONAL.

no patients during covid pandemic

Phase II Prostate Cancer trial by Ivan de Kouchkovsky, MD. Stop reason: OPERATIONAL.

Due to funding

Phase II Ulcerative Colitis trial by AstraZeneca. Stop reason: OPERATIONAL.

Strategic decision to discontinue the development of brazikumab in inflammatory bowel disease.

Phase II Locally Advanced Malignant Solid Neoplasm trial by National Cancer Institute (NCI). Stop reason: OPERATIONAL.

Other - study has reached accrual goal for analysis

Phase I Solid Tumors trial by Boehringer Ingelheim. Stop reason: OPERATIONAL.

Sponsor decision

Phase I Ovarian Cancer trial by Novartis Pharmaceuticals. Stop reason: OPERATIONAL.

Study termination based on sponsor decision due to lack of tolerability observed with \[177Lu\]Lu-EVS459

Phase III Breast Carcinoma trial by National Cancer Institute (NCI). Stop reason: OPERATIONAL.

Closed early due to slow accrual

Phase II Crohn's Disease trial by AstraZeneca. Stop reason: OPERATIONAL.

Strategic decision to discontinue the development of brazikumab in inflammatory bowel disease.

Phase II Ulcerative Colitis trial by AstraZeneca. Stop reason: OPERATIONAL.

Strategic decision to discontinue the development of brazikumab in inflammatory bowel disease.

Phase I Healthy Adult Volunteers trial by NIBEC Co., Ltd.. Stop reason: OPERATIONAL.

Study was terminated at the end of Part A for strategic reasons (not due to lack of efficacy or safety issues

Phase II Pain, Postoperative trial by University of Florida. Stop reason: OPERATIONAL.

PI left institution.

Phase I Advanced Solid Tumors trial by Debiopharm International SA. Stop reason: OPERATIONAL.

This trial was concluded for strategic reasons.

Phase I Advanced HR+/HER2- Breast Cancer trial by Novartis Pharmaceuticals. Stop reason: OPERATIONAL.

Business decision

Phase I Solid Tumors trial by Amgen. Stop reason: OPERATIONAL.

Sponsor Decision

Phase II Pain, Postoperative trial by Rutgers, The State University of New Jersey. Stop reason: OPERATIONAL.

This study never got funded. It is not feasible to conduct this study without funding.

Phase III Hyperphosphatemia Related to Chronic Kidney Disease trial by Keryx Biopharmaceuticals. Stop reason: OPERATIONAL.

Sponsor decision

Phase II Respiratory Syncytial Virus Infections trial by Shanghai Ark Biopharmaceutical Co., Ltd.. Stop reason: OPERATIONAL.

The study was terminated early due to COVID-19-related enrollment disruptions, not as a result of any product safety concerns.

Phase III NSCLC (Advanced Non-small Cell Lung Cancer) trial by ImmunityBio, Inc.. Stop reason: OPERATIONAL.

Sponsor decision

Phase II FSGS trial by Apellis Pharmaceuticals, Inc.. Stop reason: OPERATIONAL.

Study temporarily suspended due to company acquisition and ongoing strategic evaluation, with recruitment challenges including screening failures

Phase I Severe Aplastic Anemia (SAA) trial by Regeneron Pharmaceuticals. Stop reason: OPERATIONAL.

Sponsor Decision

Phase II Crohn Disease trial by Mayo Clinic. Stop reason: OPERATIONAL.

Sponsor discontinued placebo. Unable to meet enrollment goals.

Phase III Asthma trial by AstraZeneca. Stop reason: OPERATIONAL.

The study was discontinued due to slow recruitment, resulting from evolving clinical practices that reduced the use of maintenance oral corticosteroids for severe asthma treatment. The termination decision was not related to safety concerns.

Phase I Desmoplastic Small Round Cell Tumor trial by National Cancer Institute (NCI). Stop reason: OPERATIONAL.

Other - Stage 1 has met accrual

Phase II Hepatocellular Carcinoma trial by University of Texas Southwestern Medical Center. Stop reason: OPERATIONAL.

The decision was made to close the study to enrollment due to poor overall accrual and the inability to meet the 31% overall enrollment goal.

Phase II Metastatic Pancreatic Adenocarcinoma trial by Mayo Clinic. Stop reason: OPERATIONAL.

Low/slow accrual

Phase IV Pregnancy Preterm trial by University Hospitals Cleveland Medical Center. Stop reason: OPERATIONAL.

Low enrollment

Phase IV Clostridia Difficile Colitis trial by Ohio State University. Stop reason: OPERATIONAL.

Difficulties with enrollment and inability to guarantee further study drug supply after current supply expired.

Phase II Multiple Myeloma (MM) trial by Regeneron Pharmaceuticals. Stop reason: OPERATIONAL.

Sponsor Decision

Phase II Glycogen Storage Disease Type IB trial by Xinhua Hospital, Shanghai Jiao Tong University School of Medicine. Stop reason: OPERATIONAL.

The study was not initiated because the planned prospective design was no longer feasible in routine clinical practice before participant enrollment.

Phase IV Endometriosis trial by University of Louisville. Stop reason: OPERATIONAL.

Principal investigator did not have the necessary staffing resources to continue the study.

Phase II Panic Disorder trial by HB BioTech, LLC. Stop reason: OPERATIONAL.

Recruitment paused for Data Monitoring Committee (DMC) to review interim analysis data.

Phase I Advanced Solid Tumor trial by Cullinan Therapeutics Inc.. Stop reason: OPERATIONAL.

Company decision

Phase I Sickle Cell Disease trial by Fulcrum Therapeutics. Stop reason: OPERATIONAL.

Sponsor decision

Phase I Ovarian Cancer trial by NewLink Genetics Corporation. Stop reason: OPERATIONAL.

Company decision

Phase III Azoospermia, Nonobstructive trial by Hospices Civils de Lyon. Stop reason: OPERATIONAL.

problems of feasibility

Phase IV Nail Psoriasis trial by Weill Medical College of Cornell University. Stop reason: OPERATIONAL.

The study was terminated due to slow accrual.

Phase IV Posttraumatic Stress Disorder trial by VA Office of Research and Development. Stop reason: OPERATIONAL.

difficulty meeting recruitment goals

Phase I Brain Metastases trial by Medical College of Wisconsin. Stop reason: OPERATIONAL.

Study never started.

Phase IV Diabetes Mellitus, Type 2 trial by University of Illinois at Chicago. Stop reason: OPERATIONAL.

Low recruitment rate and an inability to meet power.

Phase III Retinopathy of Prematurity trial by Jaeb Center for Health Research. Stop reason: OPERATIONAL.

Lack of feasibility to recruit.

Phase IV Otitis Media trial by Boston Children's Hospital. Stop reason: OPERATIONAL.

There was limited enrollment in the study.

Phase IV Primary Pulmonary Arterial Hypertension trial by Heidelberg University. Stop reason: OPERATIONAL.

Strategic re-prioritization by the IMP supplier. Decision not safety-related

Phase III Persistent Postoperative Pain trial by Benno Rehberg-Klug. Stop reason: OPERATIONAL.

insufficient funding and recruitment